share_log

Truist Securities Maintains Buy on Sutro Biopharma, Lowers Price Target to $18

Truist Securities Maintains Buy on Sutro Biopharma, Lowers Price Target to $18

Truist Securities维持对Sutro Biopharma的买入,将目标股价下调至18美元
Moomoo 24/7 ·  04/03 09:32

Truist Securities analyst Asthika Goonewardene maintains Sutro Biopharma (NASDAQ:STRO) with a Buy and lowers the price target from $25 to $18.

Truist Securities分析师Asthika Goonewardene维持Sutro Biopharma(纳斯达克股票代码:STRO)的买入并将目标股价从25美元下调至18美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发